# A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

> **NCT07570979** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 208 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** INR731
- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone
- **DRUG:** Androgen deprivation therapy (ADT)

## Key facts

- **NCT ID:** NCT07570979
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-26
- **Primary completion:** 2030-06-03
- **Final completion:** 2030-06-03
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570979, "A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07570979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*